ライフサイエンスコーパス: peginterferon alfa-2b

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 bavirin regimens or between the two doses of peginterferon alfa-2b.

2 alfa-2b dose (3 MIU) or the once-weekly (QW) peginterferon alfa-2b (0.5, 1.0, or 1.5 microg/kg).

3 infection were randomly assigned to receive peginterferon alfa-2b 1.5 mug/kg plus ribavirin 800-1400

4 00 mg/day) (n = 58 in the final analysis) or peginterferon alfa 2b (1.5 mcg/kg/wk), ribavirin (1000-1

5 eginterferon alfa 2a (180 microg/wk; 43%) or peginterferon alfa 2b (1.5 microg /kg/wk; 44%) compared

6 .5% (95% CI, 19.9 to 27.2) for standard-dose peginterferon alfa-2b, 20.0% (95% CI, 16.4 to 23.6) for

7 among the regimens: 39.8% with standard-dose peginterferon alfa-2b, 38.0% with low-dose peginterferon

8 3 to 6.0) between standard-dose and low-dose peginterferon alfa-2b and -1.1% (95% CI, -5.3 to 3.0) be

9 16) or low-dose ribavirin (400-1000 mg) plus peginterferon alfa-2b and boceprevir three times a day f

10 (95% CI, -5.3 to 3.0) between standard-dose peginterferon alfa-2b and peginterferon alfa-2a.

11 00-1400 mg daily for 48 weeks (PR48; n=104); peginterferon alfa-2b and ribavirin daily for 4 weeks, f

12 white patients with chronic hepatitis C with peginterferon alfa-2b and ribavirin for 48 weeks.

13 e a lower rate of response to treatment with peginterferon alfa-2b and ribavirin than non-Hispanic wh

14 In all three groups, peginterferon alfa-2b and ribavirin were administered fo

15 WIN-R (Weight-based dosing of pegINterferon alfa-2b and Ribavirin) was a multicenter,

16 virus oral protease inhibitor, when added to peginterferon alfa-2b and ribavirin.

17 b, 20.0% (95% CI, 16.4 to 23.6) for low-dose peginterferon alfa-2b, and 31.5% (95% CI, 27.9 to 35.2)

18 e peginterferon alfa-2b, 38.0% with low-dose peginterferon alfa-2b, and 40.9% with peginterferon alfa

19 eks of treatment with one of three regimens: peginterferon alfa-2b at a standard dose of 1.5 microg p

20 ate was not dose-related above 1.0 microg/kg peginterferon alfa-2b because of a higher relapse rate a

21 All 3 peginterferon alfa-2b doses decreased liver inflammation

22 All 3 peginterferon alfa-2b doses significantly (P < or =.042)

23 response during treatment with 1.5 microg/kg peginterferon alfa-2b in patients infected with genotype

24 In conclusion, peginterferon alfa-2b maintained (0.5 microg/kg) or surp

25 lve by week 8 were randomized to once weekly peginterferon alfa-2b monotherapy (1.5 microg/kg per wee

26 Peginterferon alfa-2b monotherapy in acute hepatitis C i

27 Treatment guidelines recommend the use of peginterferon alfa-2b or peginterferon alfa-2a in combin

28 fa-2a (P=0.20 for standard-dose vs. low-dose peginterferon alfa-2b; P=0.57 for standard-dose peginter

29 te among patients treated with 1.5 microg/kg peginterferon alfa-2b, particularly among patients infec

30 Boceprevir (BOC) added to peginterferon alfa-2b (PegIFN) and ribavirin (RBV) signi

31 up, double-blind dose-finding study compared peginterferon alfa-2b (PegIntron) to interferon alfa-2b

32 imeprevir to either peginterferon alfa 2a or peginterferon alfa 2b plus ribavirin improved SVR in tre

33 fa-2b regimens and between the standard-dose peginterferon alfa-2b regimen and the peginterferon alfa

34 afety and adverse-event profiles between the peginterferon alfa-2b regimens and between the standard-

35 and ribavirin daily for 4 weeks, followed by peginterferon alfa-2b, ribavirin, and boceprevir 800 mg

36 4; n=103) or 44 weeks (PR4/PRB44; n=103); or peginterferon alfa-2b, ribavirin, and boceprevir three t

37 interferon alfa-2b; P=0.57 for standard-dose peginterferon alfa-2b vs. peginterferon alfa-2a).

38 Peginterferon alfa-2b was well tolerated.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。